What is it?
What P21 is
P21 usually refers to Peptide 021/P021, a synthetic CNTF-derived peptide mimetic reported as Ac-DGGLAG-NH2 and modified with an adamantane group in the Peptide 021 PubChem record. It is discussed as a neurotrophic research compound, not as a conventional supplement nutrient.
Names, aliases and forms
Mechanisms of action
CNTF/LIF/BDNF pathway context
The P021 review describes activity around LIF signaling inhibition and increased BDNF expression, with downstream discussion of neurogenesis, synaptic repair, and tau phosphorylation pathways. These mechanisms are research hypotheses and preclinical findings, not consumer outcomes.
Potential effects and evidence map
P21/P021 has preclinical evidence for memory and neurotrophic effects in mice, including the 2010 FEBS Letters P21 paper and later P021 disease-model studies. These data do not establish human efficacy, consumer nasal-spray dosing, or long-term safety. Product rows are sparse and partly mismatched, so this profile should be read as research context rather than a consumer protocol.
P21/P021 improved learning or memory-related outcomes in mouse studies, but human memory benefit has not been demonstrated.
Preclinical studies report neurogenesis, synaptic-plasticity, BDNF/LIF-pathway, tau, or dendritic markers, but these are not validated consumer outcomes.
No reliable human focus or attention benefit was found.
No reliable mood or wellbeing benefit was found.
Typical dosages and timing
The relevant indexed legacy rows are P21 Spray and P21 Peptide, but they do not provide a usable dose field. Animal routes and doses should not be converted into a nasal spray, capsule, or vial protocol.
Timing & effect horizon
Mouse studies used controlled study designs over days, weeks, or developmental windows. Those timelines do not establish onset, duration, cycling, washout, or repeat-use safety for humans.
Safety, side effects and risk profile
Human efficacy, dose, route, pharmacokinetics, and long-term safety for consumer P21 products lack validation.
Reviewed sources did not identify P21/P021 sprays or peptide products as normal dietary supplements; research-peptide, medicine, import, and claim rules vary by jurisdiction.
Interactions with neurological drugs, psychiatric medicines, seizure-threshold drugs, growth-factor pathways, immunomodulators, or experimental peptides have not been adequately studied.
No pregnancy or lactation safety basis was found for P21/P021 products; developmental mouse studies are not a human safety basis.
Human tolerability is poorly characterized; nasal, injection, peptide-vial, or excipient reactions could include headache, dizziness, irritation, allergy, or neurological symptoms.
Human metabolism, renal clearance, liver effects, and repeat-cycle safety for consumer P21/P021 products were not characterized in reviewed sources.
CNS effects in humans are not characterized, so driving, operating equipment, or combining with sedatives/stimulants is not a safe assumption.
The animal papers cannot answer human nasal, oral, or injectable tolerability; immunogenicity; excipient reactions; sterility; endotoxin exposure; contamination; neurological adverse effects; or long-term neurodevelopmental risk.
Several P021 studies intentionally used prenatal or early postnatal animal treatment windows. That makes pregnancy, lactation, childhood, fertility, epilepsy, psychiatric, and neurodevelopmental contexts especially inappropriate for self-experimentation.
Interactions and cautions
Avoid stacking P21/P021 with cognitive enhancers, antidepressants, antipsychotics, stimulants, sedatives, seizure-threshold drugs, dopaminergic medicines, immunomodulators, growth-factor agents, or other experimental peptides. Interaction data is too sparse to interpret symptoms safely.
Legal and regulatory status
Reviewed sources did not establish P21/P021 as a normal dietary supplement. Nasal sprays, injectable peptides, research chemicals, importation, medical claims, and sport or workplace testing rules can differ by country and vendor.
How it compares
The literature includes P21 (Ac-DGGLAG-NH2), P021/Peptide 021, Peptide 6, and Peptide 6c/GDDL in related CNTF-derived programs. Vendor labels may compress these names. Compare sequence, modifications, PubChem CID, and route before assuming two listings refer to the same compound.
Practical buying and quality notes
- The indexed P21 set includes legacy Nootropicsource P21 Spray and P21 Peptide rows plus unrelated HerbsPro probiotic and deodorant rows. Ignore unrelated catalog matches and verify exact P21/P021 identity before comparing listings.
- For any peptide listing, check sequence, modifications, counterion/salt, purity method, mass-spectrometry identity, residual solvents, endotoxin, sterility, preservative/excipient profile, storage, expiry, batch-specific COA, and whether the route is spray, oral, or vial.
FAQ
Is P21 a proven nootropic?
No. P21/P021 has animal memory and neurogenesis evidence, but reviewed sources did not show validated human nootropic trials or consumer dosing.
What is the P21 dose?
A validated human dose was not found. Animal doses and product rows should not be converted into a nasal spray, capsule, or injection schedule.
Is P21 the same as P021?
Many supplement and peptide discussions use P21, P021, and Peptide 021 loosely. The safer approach is to verify sequence Ac-DGGLAG-NH2, adamantane modification, PubChem CID 56589645, and vendor documentation.
Can P21 help Alzheimer disease?
P021 has Alzheimer-model mouse studies, including 3xTg-AD work, but that is not the same as a human Alzheimer treatment. Do not treat preclinical disease-model findings as medical evidence for people.
Who should avoid P21 products?
Avoid self-directed use with pregnancy, lactation, childhood, epilepsy, neurodevelopmental disorders, psychiatric instability, neurodegenerative disease treatment, immunomodulating drugs, peptide allergy, unclear identity, or non-sterile route concerns.
References
- PubChem. Peptide 021 (CID 56589645). Accessed 2026-07-01.
- Li B, et al. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Lett. 2010.
- Blanchard J, et al. Beneficial effect of a CNTF tetrapeptide on adult hippocampal neurogenesis, neuronal plasticity, and spatial memory in mice. J Alzheimers Dis. 2010.
- Chohan MO, et al. Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury. Neurosurgery. 2015.
- Kazim SF, et al. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair. Mol Neurodegener. 2016.
- Baazaoui N, et al. Prevention of amyloid-beta and tau pathologies, neurodegeneration, and cognitive deficit by early treatment with a neurotrophic compound. J Alzheimers Dis. 2017.
- Kazim SF, et al. Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice. Alzheimers Res Ther. 2020.
- Kazim SF, et al. Neurotrophic treatment initiated during early postnatal development prevents Alzheimer-like behavior and synaptic dysfunction. J Alzheimers Dis. 2021.
- Lucchino V, et al. Effects of a CNTF small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. J Neurodev Disord. 2024.